Ethics body approves another clinical trial using MGC Pharma’s epilepsy drug

Share on facebook
Share on twitter
Share on linkedin


MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison assessing the efficacy of low-THC to 100 per cent CBD products when treating severe intractable epilepsy.

Read more :

More to explorer

making nicotine-containing vape liquid

Can vaping help me quit smoking?

Vaping laws changed in Australia on 1st October 2021, making nicotine-containing vape liquid a Schedule 4 prescription-only medicine.